FDA approves sBLA for Takeda's Vonvendi for Von Willebrand disease
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Edwards’ latest-generation balloon-expandable transcatheter heart valve incorporates a proprietary calcification-resistant tissue technology
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Subscribe To Our Newsletter & Stay Updated